Abstract
This report presents the clinical and bacteriological assessment of a twice daily formulation of erythromycin stearate. The activity of this twice daily formulation was compared with erythromycin stearate 250 mg 6 hourly, and the assessment carried out in a number of general practices, both urban and rural, distributed widely throughout the United Kingdom. The twice daily dosage regime of ‘Erythrocin 500’ was seen to be an effective therapy, to compare favourably with the smaller dose given 6 hourly and with minimal side-effects. Antibiotic sensitivity tests included penicillin and tetracycline as well as erythromycin, and the negligible incidence of resistance demonstrated for erythromycin contrasted with that of the two other commonly used antibiotics.
Get full access to this article
View all access options for this article.